Valuation: Kuros Biosciences AG

Market Cap 891M 1.11B 952M 816M 1.53B 106B 1.55B 10.53B 4.11B 53.43B 4.17B 4.08B 177B P/E 2026 *
109x
P/E 2027 * 46.7x
Enterprise Value 880M 1.1B 941M 806M 1.51B 105B 1.53B 10.4B 4.06B 52.79B 4.12B 4.03B 175B EV / Sales 2026 *
5.28x
EV / Sales 2027 * 3.8x
Free-Float
71.26%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 2023-10-11
Chief Executive Officer 60 2017-12-03
Director of Finance/CFO - 2023-02-16
Director TitleAgeSince
Chairman 69 2018-06-13
Director/Board Member 60 2018-06-13
Director/Board Member 57 2018-06-13
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 1.12B
-3.00%+0.33%+77.39%+109.41% 73.96B
+1.90%+23.53%+56.60%+97.76% 64.66B
+0.84%+2.18%-4.65%+474.73% 27.32B
+4.20%+22.91%+3.30%-2.65% 27.86B
+2.74%+11.55%+66.56%+27.34% 25.97B
+0.47%+6.12%+36.66%-13.79% 19.98B
+1.82%-3.11%+245.72%+423.83% 17.84B
+0.94%+2.38%+24.83%+552.12% 16.24B
+1.10%+5.72%+39.94%+153.49% 13.3B
Average +1.11%+6.16%+60.70%+202.47% 31.9B
Weighted average by Cap. +0.65%+6.66%+59.65%+161.30%

Financials

2026 *2027 *
Net sales 167M 208M 178M 153M 286M 19.89B 290M 1.97B 768M 9.99B 781M 764M 33.05B 224M 279M 239M 205M 384M 26.69B 389M 2.64B 1.03B 13.41B 1.05B 1.02B 44.35B
Net income 9.32M 11.63M 9.96M 8.53M 16.01M 1.11B 16.22M 110M 42.95M 559M 43.67M 42.72M 1.85B 21.65M 27.01M 23.14M 19.82M 37.19M 2.58B 37.69M 256M 99.75M 1.3B 101M 99.22M 4.29B
Net Debt -10.7M -13.34M -11.43M -9.79M -18.37M -1.28B -18.62M -126M -49.28M -641M -50.11M -49.02M -2.12B -41.26M -51.47M -44.09M -37.76M -70.87M -4.92B -71.81M -487M -190M -2.47B -193M -189M -8.18B
Logo Kuros Biosciences AG
Kuros Biosciences AG is a Switzerland‑based biotechnology company engaged in the research, development, and commercialization of biologic technologies for musculoskeletal care, with a focus on those supporting bone regeneration and bone growth. The Company's key product is MagnetOs, which is a synthetic bone graft technology available in multiple formats such as granules or putty. MagnetOs is designed to stimulate bone formation, including through mechanisms that engage the body’s immune response. The technology behind MagnetOs is associated with osteoimmunology, which involves immune‑modulated bone healing. MagnetOs uses the proprietary NeedleGrip submicron surface technology, which supports bone growth by enhancing biological responses related to healing. It is indicated for use across the skeletal system and is positioned as a bone graft option for procedures involving various anatomical regions.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
22.46CHF
Average target price
33.92CHF
Spread / Average Target
+51.00%

Quarterly revenue - Rate of surprise